Abbvie Inc

AbbVie develops and commercializes advanced biologic therapies and small molecule drugs addressing immunology conditions like rheumatoid arthritis and psoriasis, oncology treatments, and neuroscience disorders. The company's revenue engine centers on blockbuster immunology drugs including Skyrizi and Rinvoq, which are replacing legacy product Humira. AbbVie also operates aesthetics and neuroscience divisions through its Allergan acquisition, selling Botox and migraine treatments. The business model emphasizes high-margin specialty pharmaceuticals protected by patent exclusivity.

AbbVie offers investors strong cash flow generation and an above-average dividend yield around 3%. The company's growth depends on successfully transitioning revenue from Humira biosimilar erosion to newer immunology franchises. Strengths include a robust pipeline and proven drug commercialization capabilities. Risks involve patent cliffs, clinical trial failures, regulatory hurdles, and pricing pressures. The stock often trades at moderate valuations reflecting both growth opportunities and pharmaceutical industry execution risks.

Johnson & Johnson competes in immunology with Stelara and Tremfya. Amgen rivals in biosimilars and inflammation treatments like Enbrel. Bristol Myers Squibb competes across oncology and immunology. Eli Lilly challenges in immunology and neuroscience markets. Pfizer competes through diverse therapeutic areas including inflammation and oncology biologics.

AbbVie has demonstrated a commitment to dividend growth since spinning off from Abbott Laboratories in 2013, increasing payouts annually. The company targets a competitive yield typically above 3%, supported by strong operating cash flows from its pharmaceutical portfolio. Management emphasizes returning capital to shareholders through both dividends and share repurchases, maintaining payout ratios sustainable relative to earnings and free cash flow generation.

ABBV last closed at $211.12, up 1.90% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $164.39 and a high of $244.81. The current price represents 58% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 39 analysts covering ABBV, the consensus rating is Buy — 27 rate it a buy, 12 hold, and 0 sell. The average price target sits at $257.58, implying 22% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Abbvie Inc generated $55.26B in revenue during fiscal year 2026, with $4.20B reaching the bottom line as net income. The net profit margin of 7.6% reflects the competitive nature of its industry.

ABBV trades at a P/E ratio of 166.57 on trailing earnings of $1.35 per share. That's well above the S&P 500 historical average of ~20-25x, which typically signals that investors are pricing in aggressive future growth. Comparing this multiple against Biotechnology sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -8.54% (3M), -5.40% (6M), +4.14% (1Y), -7.93% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether ABBV is outperforming or lagging the broader market.